Fig. 5

MIR31HG increased the expression of an endogenous miR-575 target, ST7L. a and b qRT-PCR and Western blot analysis for MIR31HG regulating ST7L expressions in SMMC7721 and HepG2 cells (**P < 0.01 versus pcDNA3.1 group; ##P < 0.01 versus sh-NC group). c and d qRT-PCR and Western blot analysis for miR-575 regulating ST7L expressions in SMMC7721 and HepG2 (**P < 0.01 versus pre-NC group; ##P < 0.01 versus anti-NC group). e The predicted miR-575 binding sites in ST7L 3’UTR (ST7L-3’UTR-WT) or and the designed mutant sequence (ST7L-3’UTR-MUT) were indicated. f Luciferase reporter assay of 293 T and SMMC7721 cells co-transfected with ST7L-3’UTR-WT or ST7L-3’UTR-MUT and pre-NC or pre-miR-575 (**P < 0.01 versus MIR31HG-WT + pre-NC group). g and h qRT-PCR and Western blot analysis of ST7L expressions in L02 cells and HCC cell lines (**P < 0.01). i qRT-PCR analysis of ST7L expressions in 42 pairs of HCC tissues and adjacent non-tumor tissues (P < 0.01). j Western blot analysis of ST7L expressions in 4 pairs of HCC tissues (T) and adjacent non-tumor tissues (N). k The expression of MIR31HG was positively correlated with that of ST7L (r = 0.6067, P < 0.01) in clinical specimens. l The expression of miR-575 was negatively correlated with that of ST7L (r = − 0.6224, P < 0.01) in clinical specimens